A National Academies of Science, Engineering and Medicine workshop focusing on the US National Institutes of Health’s role in drug development and its “impact on access” sounded like it might be a starting point to develop data and potential metrics to build a framework to enable assertion of “march-in” rights on high priced drugs.
When NASEM set the workshop for July 24-25, sponsored by the John & Laura Arnold Foundation and entitled “The Role...






